Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02445963
Recruitment Status : Active, not recruiting
First Posted : May 15, 2015
Last Update Posted : April 11, 2019
Sponsor:
Information provided by (Responsible Party):
U.S. Army Medical Research and Materiel Command

Brief Summary:
This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a InvaplexAR vaccine. A total of up to 40 subjects will receive one of four S. flexneri 2a InvaplexAR vaccine doses. The vaccine will be administered intranasally (without adjuvant).

Condition or disease Intervention/treatment Phase
Shigellosis Bacillary Dysentery Biological: Shigella flexneri 2a InvaplexAR Phase 1

Detailed Description:
The vaccine will be administered on Days 0,14, and 28. Volunteers (10 per group [8 minimum]) will receive the same dose at each vaccination dependent upon group assignment. Groups will be divided according to the table below. An interval no less than 1 week will separate the third dose of a group from the first dose of the next group (receiving an increased InvaplexAR dose). Blood, stool, and saliva specimens will be collected at pre-specified intervals to examine systemic and mucosal vaccine antigen-specific immune responses. Ocular tear samples will be collected in groups C and D. Vaccine safety will be actively monitored during vaccination and for 28 days following the third vaccine dose. The decision to advance to the next dose level is based on the safety assessment (not immunogenicity). A dose level with no occurrence of stopping criteria in the 7 days following the last vaccine dose will prompt moving to the next higher level. All safety data will be summarized and reviewed with the research monitor prior to dose escalation. In addition, a report of all safety data will be provided to the sponsor's safety office for informational purposes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity
Actual Study Start Date : October 1, 2015
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 10 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
Biological: Shigella flexneri 2a InvaplexAR
The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.

Active Comparator: 50 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
Biological: Shigella flexneri 2a InvaplexAR
The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.

Active Comparator: 250 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
Biological: Shigella flexneri 2a InvaplexAR
The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.

Active Comparator: 500 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
Biological: Shigella flexneri 2a InvaplexAR
The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.




Primary Outcome Measures :
  1. Number of adverse events [ Time Frame: 270 days ]
    Solicited AE monitoring will survey and specifically inquire about symptoms including subjective and objective fever (oral temperature > 100.4°F), malaise, headache, rhinorrhea, epistaxis (nasal bleeding), nasal mucosal ulceration, nasal congestion, edema, nasal burning, nasal itching, nasal discharge, sore throat, post nasal drip, cough, sinus pain, sneezing, and itchy eyes.

  2. Antibody titers against immunizing antigens [ Time Frame: 56 days ]
    Serum samples will be assayed for antibody titers against immunizing antigens. Previously established high-titer specimens will be included on each plate to track day to day interassay variation. For each antigen, pre- and post-vaccination serum samples will be assayed side-by-side. The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days. Reciprocal endpoint titers < 5 will be assigned a value of 2.5 for computational purposes. Seroconversion will be defined as a > 4-fold increase in endpoint titer between pre-and post-vaccination samples AND a post-vaccination reciprocal titer >10.


Secondary Outcome Measures :
  1. Mucosal responses (Number of IgA Antibody Secreting Cells (ACS) and Antibody lymphocyte supernatant (ALS) responses). [ Time Frame: 56 days ]

    Peripheral Blood Mononuclear Cells (PBMCs) will be collected to determine IgA Antibody Secreting Cells (ACS) and Antibody lymphocyte supernatant (ALS) responses.

    Fecal and salivary IgA samples will be obtained to assess for mucosal IgA




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of enrollment.
  • Completion and review of comprehension test (achieved > 70% accuracy).
  • Signed informed consent document.
  • Available for the required follow-up period and scheduled clinic visits.
  • Women: Negative pregnancy test with understanding (through informed consent process) to not become pregnant nor to breastfeed during the study or within 3 months following last vaccination

Exclusion Criteria:

  • Health problems (for example, chronic medical conditions such as psychiatric conditions, diabetes mellitus, hypertension, or any other conditions that might place the subjects at increased risk of adverse events)- study clinicians, in consultation with the PI, will use clinical judgment on a case-by-case basis to assess safety risks under this criterion. The PI will consult with the Research Monitor as appropriate.
  • Clinically significant abnormalities on physical examination (chronic sinusitis or seasonal rhinitis) which compromise identification and interpretation of potential vaccine associated adverse effects.
  • Use of immunosuppressive and/or immunomodulative drugs such as corticosteroids or chemotherapeutics that may influence antibody development.
  • Immunosuppressive illnesses (including IgA deficiency defined by serum IgA below level of detection or <7mg/dL).
  • Participation in research involving another investigational product (defined as receipt of an investigational product or exposure to an invasive investigational device) 30 days before planned date of first vaccination or anytime throughout the duration of the study until the last study safety visit.
  • Positive blood test for HBsAG, HCV, HIV-1/HIV-2.
  • Clinically significant abnormalities on basic laboratory screening.
  • Presence of significant unexplained laboratory abnormalities that in the opinion of the PI may potentially confound the analysis of the study results.
  • Current smoker or smoker in past 1 year ('smoker' defined as daily cigarette, cigar, or pipe use for a period of at least 1 month).

Research specific

  • Structural abnormalities on sinus/nasal cavity examination.
  • Rhinoplasty.
  • Nasal polyps.
  • Nasal ulcers.
  • Deviated nasal septum. This question is being used to determine whether the volunteer has a clinically significant deviated septum that causes nasal obstruction (thereby causing difficulty breathing), interferes with normal sinus drainage, or obscures visualization of the posterior nasal cavity complicating examination and safety monitoring..
  • Chronic sinusitis/rhinitis.
  • Current or planned use of nasal topical corticosteroids and/or nasal spray medications in the 4 weeks prior to dosing or during the study vaccination period.
  • Current or recent history (in the past 5 years) of reactive airway disease (asthma), chronic obstructive pulmonary disease, or chronic bronchitis.
  • History of Bell's palsy.
  • Chronic use (weekly or more often) of anti-diarrheal, anti-constipation, or antacid therapy (excluding use associated with spicy meals).
  • Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on a regular basis; loose or liquid stools on other than an occasional basis.
  • Personal or family history of inflammatory arthritis.
  • Positive blood test for HLA-B27.
  • History of allergy to any vaccine.

Prior Exposure to Shigella

  • Serum IgG titer ≥ 2500 to Shigella flexneri 2a LPS.
  • History of microbiologically confirmed Shigella infection in the past 3 years.
  • Received previous experimental Shigella vaccine or live Shigella challenge.
  • Travel to countries with symptoms of travelers' diarrhea where Shigella or other enteric infections are endemic (most of the developing world) within the past 6 months prior to dosing.
  • Occupation involving handling of Shigella bacteria currently, or in the past 3 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02445963


Locations
Layout table for location information
United States, Maryland
Walter Reed Army Institute of Research, Clinical Trials Center
Silver Spring, Maryland, United States, 20910
Sponsors and Collaborators
U.S. Army Medical Research and Materiel Command
Investigators
Layout table for investigator information
Principal Investigator: Christopher Duplessis, MD, MPH, MS Enteric Diseases Department Naval Medical Research Center

Layout table for additonal information
Responsible Party: U.S. Army Medical Research and Materiel Command
ClinicalTrials.gov Identifier: NCT02445963     History of Changes
Other Study ID Numbers: S-15-19
A-18716 ( Other Identifier: Walter Reed Army Institute of Research )
NMRC.2015.0003 ( Other Identifier: Naval Medical Research Center )
First Posted: May 15, 2015    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: April 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Dysentery
Dysentery, Bacillary
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections